Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB.

Clin Cancer Res. 2018 Aug 6. doi: 10.1158/1078-0432.CCR-17-3668. [Epub ahead of print]

PMID:
30082477
2.

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.

3.

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M.

J Hematol Oncol. 2018 May 30;11(1):71. doi: 10.1186/s13045-018-0616-2.

4.

Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.

Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC).

Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13. Erratum in: Lancet Gastroenterol Hepatol. 2018 Jun;3(6):e3.

PMID:
29548617
5.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2018 Jan;118(2):e2. doi: 10.1038/bjc.2017.418. Epub 2018 Jan 9. No abstract available.

6.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T.

J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

7.

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.

Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M.

Oncologist. 2017 Jul;22(7):804-810. doi: 10.1634/theoncologist.2016-0415. Epub 2017 May 9. Review.

8.

Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.

Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, Kaseb A, Shroff RT.

J Gastrointest Oncol. 2017 Apr;8(2):347-351. doi: 10.21037/jgo.2017.03.03.

9.

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.

Shroff RT, Yarchoan M, O'Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Subbiah V, Zinner R, Azad NS.

Br J Cancer. 2017 May 23;116(11):1402-1407. doi: 10.1038/bjc.2017.119. Epub 2017 Apr 25. Erratum in: Br J Cancer. 2018 Jan 09;:.

10.

Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.

Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ.

Cancer. 2017 May 15;123(6):1011-1017. doi: 10.1002/cncr.30445. Epub 2016 Nov 14.

11.

Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE.

J Gastrointest Surg. 2017 Jan;21(1):164-174. doi: 10.1007/s11605-016-3265-1. Epub 2016 Oct 24.

PMID:
27778257
12.

BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype.

Al-Shamsi HO, Anand D, Shroff RT, Jain A, Zuo M, Conrad C, Vauthey JN, Javle MM.

J Gastrointest Oncol. 2016 Aug;7(4):556-61. doi: 10.21037/jgo.2016.03.05.

13.

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.

Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S.

Oncotarget. 2016 Oct 11;7(41):67495-67506. doi: 10.18632/oncotarget.11317.

14.

Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.

Ahn DH, Javle M, Ahn CW, Jain A, Mikhail S, Noonan AM, Wu C, Shroff RT, Chen JL, Bekaii-Saab T.

Cancer. 2016 Dec 1;122(23):3657-3666. doi: 10.1002/cncr.30247. Epub 2016 Aug 6. Erratum in: Cancer. 2017 Jun 15;123(12 ):2376.

15.

Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.

Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH.

Cancer. 2016 Sep 1;122(17):2671-9. doi: 10.1002/cncr.30117. Epub 2016 May 31.

16.

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.

Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH.

J Clin Oncol. 2016 Jan 20;34(3):219-26. doi: 10.1200/JCO.2015.61.3778. Epub 2015 Oct 26.

17.

Consensus conference on gallbladder cancer.

Shroff RT, Knox J, Dixon E.

HPB (Oxford). 2015 Aug;17(8):664-5. doi: 10.1111/hpb.12432. No abstract available.

18.

Underuse of surgical resection among elderly patients with early-stage pancreatic cancer.

He W, Zhao H, Chan W, Lopez D, Shroff RT, Giordano SH.

Surgery. 2015 Nov;158(5):1226-34. doi: 10.1016/j.surg.2015.04.031. Epub 2015 Jun 29.

PMID:
26138347
19.

Second-line systemic treatment for advanced cholangiocarcinoma.

Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT.

J Gastrointest Oncol. 2014 Dec;5(6):408-13. doi: 10.3978/j.issn.2078-6891.2014.072.

20.

Molecular characterization of gallbladder cancer using somatic mutation profiling.

Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic AK, Nogueras-Gonzalez GM, Janku F, Shroff RT, Aloia TA, Vauthey JN, Curley S, Mills G, Roa I.

Hum Pathol. 2014 Apr;45(4):701-8. doi: 10.1016/j.humpath.2013.11.001. Epub 2013 Nov 12.

21.

The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy.

Shroff S, Overman MJ, Rashid A, Shroff RT, Wang H, Chatterjee D, Katz MH, Lee JE, Wolff RA, Abbruzzese JL, Fleming JB, Wang H.

Arch Pathol Lab Med. 2013 Nov;137(11):1619-26. doi: 10.5858/arpa.2012-0418-OA.

22.

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL.

BMC Cancer. 2010 Jul 14;10:368. doi: 10.1186/1471-2407-10-368.

Supplemental Content

Loading ...
Support Center